

# Wei-Li Zhao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5666462/publications.pdf>

Version: 2024-02-01

87  
papers

6,494  
citations

279487

23  
h-index

69108

77  
g-index

98  
all docs

98  
docs citations

98  
times ranked

15651  
citing authors

#	ARTICLE	IF	CITATIONS
1	Elevated serum IL-13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2023, 41, 230-238.	0.8	6
2	Hepatitis B virus-associated follicular lymphoma presents T-cell inflamed phenotype and response to lenalidomide. <i>Cancer Communications</i> , 2022, 42, 170-174.	3.7	3
3	Integrated Genomic and Transcriptomic Analyses of Diffuse Large B-Cell Lymphoma With Multiple Abnormal Immunologic Markers. <i>Frontiers in Oncology</i> , 2022, 12, 790720.	1.3	5
4	All roads lead to targeted diffuse large B-cell lymphoma approaches. <i>Cancer Cell</i> , 2022, 40, 131-133.	7.7	7
5	Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 80.	7.1	8
6	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, 842439.	2.2	5
7	Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication. <i>Blood Cancer Journal</i> , 2022, 12, 48.	2.8	3
8	Argonaute-integrated isothermal amplification for rapid, portable, multiplex detection of SARS-CoV-2 and influenza viruses. <i>Biosensors and Bioelectronics</i> , 2022, 207, 114169.	5.3	41
9	How we treat NK/T-cell lymphomas. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	41
10	Phase I study of the anti-BTLA antibody icatolimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas. <i>Journal of Clinical Oncology</i> , 2022, 40, 7578-7578.	0.8	5
11	A phase II, multicenter, single-arm study of piasclisib, a PI3K $\gamma$ inhibitor, in relapsed or refractory follicular lymphoma in China: Updated data from the study. <i>Journal of Clinical Oncology</i> , 2022, 40, 7574-7574.	0.8	0
12	A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression. <i>Molecular Oncology</i> , 2021, 15, 246-261.	2.1	22
13	CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 10.	7.1	93
14	Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China. <i>Cancer Communications</i> , 2021, 41, 229-239.	3.7	15
15	The characteristic computed tomography findings of pulmonary B-cell non-Hodgkin's lymphoma and their role in predicting patient survival. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 772-783.	1.1	0
16	Low-Dose Decitabine Monotherapy Reverses Mixed Chimerism in Adult Patients After Allogeneic Hematopoietic Stem Cell Transplantation With Myeloablative Conditioning Regimen: A Pilot Phase II Study. <i>Frontiers in Medicine</i> , 2021, 8, 627946.	1.2	3
17	Single-Cell Transcriptome Analysis Identifies Ligand-Receptor Pairs Associated With BCP-ALL Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 639013.	1.3	4
18	CytoTree: an R/Bioconductor package for analysis and visualization of flow and mass cytometry data. <i>BMC Bioinformatics</i> , 2021, 22, 138.	1.2	18

#	ARTICLE	IF	CITATIONS
19	A novel lncRNA TCLinc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes. <i>Cell Death and Disease</i> , 2021, 12, 321.	2.7	13
20	Deauville score evaluation of interim PET/CT in primary mediastinal large B-cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3347-3350.	3.3	6
21	Diffuse large B-cell lymphoma segmentation in PET-CT images via hybrid learning for feature fusion. <i>Medical Physics</i> , 2021, 48, 3665-3678.	1.6	16
22	Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. <i>International Journal of Hematology</i> , 2021, 114, 355-362.	0.7	1
23	Implication of immune cell signature of tumor microenvironment in diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2021, 39, 616-624.	0.8	7
24	Clinical and molecular features of Epstein-Barr virus-positive diffuse large B-cell lymphoma: Results in a multicenter trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e539.	1.7	5
25	Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 638757.	1.3	6
26	SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential. <i>EBioMedicine</i> , 2021, 72, 103614.	2.7	24
27	Selective and competitive functions of the AAR and UPR pathways in stress-induced angiogenesis. <i>Cell Discovery</i> , 2021, 7, 98.	3.1	6
28	Trial in Progress: Pomalidomide Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PRIDE). <i>Blood</i> , 2021, 138, 4562-4562.	0.6	1
29	CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis. <i>Molecular Cancer</i> , 2021, 20, 153.	7.9	17
30	Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma: Phase 1/2 and biomarker study. <i>Clinical and Translational Medicine</i> , 2021, 11, e584.	1.7	8
31	Use of Complete Blood Count for Prognostic Evaluation of Peripheral T-Cell Lymphoma. <i>Acta Haematologica</i> , 2020, 143, 93-95.	0.7	0
32	Comparison of Nasopharyngeal MR, 18 F-FDG PET/CT, and 18 F-FDG PET/MR for Local Detection of Natural Killer/T-Cell Lymphoma, Nasal Type. <i>Frontiers in Oncology</i> , 2020, 10, 576409.	1.3	6
33	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma. <i>Clinical and Translational Medicine</i> , 2020, 10, e221.	1.7	46
34	setd2 knockout zebrafish is viable and fertile: differential and developmental stress-related requirements for Setd2 and histone H3K36 trimethylation in different vertebrate animals. <i>Cell Discovery</i> , 2020, 6, 72.	3.1	8
35	Prognostic impact of B vitamins involved in one-carbon metabolism in patients with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 456-466.	0.8	4
36	Single-Cell RNA Sequencing in Hematological Diseases. <i>Proteomics</i> , 2020, 20, e1900228.	1.3	16

#	ARTICLE	IF	CITATIONS
37	Advances in targeted therapy for malignant lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 15.	7.1	66
38	Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. <i>Cancer Cell</i> , 2020, 37, 403-419.e6.	7.7	136
39	A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group. <i>Leukemia</i> , 2020, 34, 2243-2248.	3.3	35
40	CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial. <i>Genome Medicine</i> , 2020, 12, 41.	3.6	7
41	Autophagy and Leukemia. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1207, 601-613.	0.8	1
42	Autophagy and Lymphoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1207, 615-623.	0.8	2
43	Autophagy and Myeloma. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1207, 625-631.	0.8	6
44	Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: Results from a phase II, single-arm, multicenter, study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20051-e20051.	0.8	3
45	Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenström Macroglobulinemia from a Phase 2 Trial. <i>Blood</i> , 2020, 136, 42-43.	0.6	3
46	Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6995-7003.	3.2	70
47	Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial. <i>Lancet Haematology</i> , 2019, 6, e328-e337.	2.2	31
48	Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma. <i>EBioMedicine</i> , 2019, 41, 167-174.	2.7	32
49	Clinical features and outcomes of pulmonary lymphoma: A single center experience of 180 cases. <i>Lung Cancer</i> , 2019, 132, 39-44.	0.9	16
50	MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells. <i>Molecular Cancer</i> , 2019, 18, 54.	7.9	65
51	A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. <i>Blood Advances</i> , 2019, 3, 4117-4130.	2.5	23
52	An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies. <i>Blood</i> , 2019, 134, 1594-1594.	0.6	7
53	Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma. <i>Translational Cancer Research</i> , 2019, 8, 1019-1026.	0.4	1
54	Cellular Kinetics and Anti-Therapeutic Antibody in Relapsed/Refractory B-NHL Patients Treated with JWCA029. <i>Blood</i> , 2019, 134, 4083-4083.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. <i>Haematologica</i> , 2018, 103, 679-687.	1.7	67
56	Targetable Metabolic Vulnerability in Diffuse Large B-Cell Lymphoma. <i>EBioMedicine</i> , 2018, 28, 5-6.	2.7	2
57	Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. <i>Cell Research</i> , 2018, 28, 172-186.	5.7	62
58	Advances in multiple omics of natural-killer/T cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 134.	6.9	27
59	Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma. <i>Cancer Science</i> , 2018, 109, 3971-3980.	1.7	16
60	Doxorubicin-loaded dextran-based nano-carriers for highly efficient inhibition of lymphoma cell growth and synchronous reduction of cardiac toxicity. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 5673-5683.	3.3	26
61	Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies. <i>EBioMedicine</i> , 2018, 33, 94-104.	2.7	10
62	Efficacy and Safety of JWCAR029 in Adult Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 4187-4187.	0.6	5
63	Metformin prolonged the survival of diffuse large B-cell lymphoma and grade 3b follicular lymphoma patients responding to first-line treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone: a prospective phase II clinical trial. <i>Translational Cancer Research</i> , 2018, 7, 1044-1053.	0.4	6
64	Synergic Effect of Histone Deacetylase Inhibitor Chidamide with Doxorubicin on Diffuse Large B-Cell Lymphoma with Double BCL2/MYC Expression. <i>Blood</i> , 2018, 132, 4104-4104.	0.6	0
65	B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study. <i>EBioMedicine</i> , 2017, 16, 106-114.	2.7	15
66	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 69.	6.9	155
67	A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type. <i>EBioMedicine</i> , 2017, 25, 41-49.	2.7	45
68	JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide. <i>Scientific Reports</i> , 2017, 7, 7433.	1.6	21
69	MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 82.	3.5	17
70	Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia. <i>Molecular Medicine Reports</i> , 2017, 16, 101-108.	1.1	8
71	Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients. <i>Mediators of Inflammation</i> , 2017, 2017, 1-9.	1.4	3
72	Novel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases. <i>Molecular and Clinical Oncology</i> , 2016, 4, 107-113.	0.4	3

#	ARTICLE	IF	CITATIONS
73	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
74	Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution. <i>World Journal of Surgical Oncology</i> , 2015, 13, 246.	0.8	12
75	MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	23
76	Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients. <i>Annals of Hematology</i> , 2015, 94, 239-247.	0.8	28
77	Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide. <i>EBioMedicine</i> , 2015, 2, 563-571.	2.7	42
78	Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation. <i>Autophagy</i> , 2015, 11, 2160-2171.	4.3	58
79	GSTT1 Deletion Is Related to Polycyclic Aromatic Hydrocarbons-Induced DNA Damage and Lymphoma Progression. <i>PLoS ONE</i> , 2014, 9, e89302.	1.1	15
80	Serum metabolite profiling of B-cell non-Hodgkin's lymphoma using UPLC-QTOFMS and GC-TOFMS. <i>Metabolomics</i> , 2014, 10, 677-687.	1.4	6
81	c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors. <i>Journal of Hematology and Oncology</i> , 2014, 7, 88.	6.9	27
82	Prognostic factors of Chinese patients with T/NK-cell lymphoma: a single institution study of 170 patients. <i>Medical Oncology</i> , 2012, 29, 2176-2182.	1.2	23
83	PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. <i>Blood</i> , 2008, 111, 3867-3871.	0.6	38
84	Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. <i>Experimental Hematology</i> , 2007, 35, 1801-1811.	0.2	26
85	Histone Deacetylase Inhibitor Promotes Rituximab-Induced Apoptosis in Non-Hodgkin's B-Lymphoma Cells by NF- $\kappa$ B-Mediated Bcl-2/Bcl-XL Downregulation and c-Myc Degradation.. <i>Blood</i> , 2006, 108, 2526-2526.	0.6	0
86	The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution. <i>The Hematology Journal</i> , 2002, 3, 137-144.	2.0	12
87	Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients. <i>Chinese Medical Journal</i> , 2002, 115, 702-4.	0.9	4